07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

Abbott sales and marketing update

Abbott launched its Architect HIV Ag/Ab combo assay in the U.S. to diagnose HIV infection in serum and plasma samples. The chemiluminescent microparticle immunoassay detects both the HIV p24 antigen and antibodies to HIV-1 (groups...
07:00 , Jun 28, 2010 |  BC Week In Review  |  Clinical News

Architect HIV Ag/Ab Combo assay regulatory update

FDA approved a PMA from Abbott for the Architect HIV Ag/Ab combo assay to diagnose HIV-1/HIV-2 infection in serum and plasma samples. The chemiluminescent microparticle immunoassay detects both HIV p24 antigen and antibodies to HIV...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

Architect HIV Ag/Ab Combo assay regulatory update

Abbott submitted a PMA to FDA for its Architect HIV Ag/Ab Combo assay to aid in the diagnosis of HIV-1/HIV-2 infection, including acute or primary HIV-1 infection. The assay, which is available in Europe, is...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Clinical News

Architect HIV Ag/Ab Combo assay diagnostic data

Data from >1,000 blood samples showed the fourth generation Architect Ag/Ab Combo assay reduced the seroconversion detection window by 0-9 days compared with HIV antibody-only assays for 4 of the 5 seroconversion panels tested. The...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Architect HIV Ag/Ab Combo assay diagnostic data

Data from 217 blood samples taken from the U.S. EXPLORE trial in HIV-seronegative men showed that Abbott's fourth-generation Architect HIV Ag/Ab Combo assay detected 13 of 21 (62%) acute HIV infections. All of the 21...